ROLE OF CVD RISK ASSESSMENT IN COPD

被引：0
|
作者：
Lee, H. M. [1 ]
Lee, J. [1 ]
Lee, K. [1 ]
Luo, Y. [1 ]
Sin, D. D. [2 ]
Wong, N. D. [1 ]
机构：
[1] Univ Calif Irvine, Irvine, CA USA
[2] St Pauls Hosp, James Hogg iCAPTURE Ctr Pulm Res, Vancouver, BC, Canada
来源：
CARDIOLOGY | 2016年 / 134卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
397
引用
收藏
页码：410 / 410
页数：1
相关论文
共 50 条
  • [1] Risk assessment in asthma and COPD: a potential role for biomarkers?
    Taylor, D. R.
    [J]. THORAX, 2009, 64 (03) : 261 - 264
  • [2] Fall Risk Assessment in COPD
    Beauchamp, M. K.
    Janaudis-Ferreira, T.
    Hill, K.
    Goldstein, R. S.
    Brooks, D.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [3] Will a web-based cardiovascular disease (CVD) risk assessment programme increase the assessment of CVD risk factors for Maori?
    Whittaker, Robyn
    Bramley, Dale
    Wells, Sue
    Stewart, Alistair
    Selak, Vanessa
    Furness, Sue
    Rafter, Natasha
    Roseman, Paul
    Jackson, Rod
    [J]. NEW ZEALAND MEDICAL JOURNAL, 2006, 119 (1238)
  • [4] Providing Evidence for Subclinical CVD in Risk Assessment
    Blaha, Michael J.
    Yeboah, Joseph
    Al Rifai, Mahmoud
    Liu, Kiang
    Kronmal, Richard
    Greenland, Philip
    [J]. GLOBAL HEART, 2016, 11 (03) : 275 - 285
  • [5] Strategies for personalized risk assessment for CVD management
    Paredes, S.
    Mendes, D.
    Rocha, T.
    Carvalho, P.
    Henriques, J.
    Morais, J.
    [J]. 2016 3RD IEEE EMBS INTERNATIONAL CONFERENCE ON BIOMEDICAL AND HEALTH INFORMATICS, 2016, : 344 - 347
  • [6] New evidence on the role of inflammation in CVD risk
    Lorenzatti, Alberto J.
    Luz Servato, Maria
    [J]. CURRENT OPINION IN CARDIOLOGY, 2019, 34 (04) : 418 - 423
  • [7] The role of postprandial hyperglycemia and hyperlipidemia in CVD risk
    Robert J. Heine
    [J]. Current Diabetes Reports, 2006, 6 (1) : 1 - 2
  • [8] Role of COPD in Evaluation of Cardiovascular Risk
    Liu M.A.
    Lee H.M.
    [J]. Current Cardiovascular Risk Reports, 2013, 7 (2) : 113 - 116
  • [9] Severe CVD risk with new use of long-acting COPD therapies
    [J]. Reactions Weekly, 2018, 1684 (1) : 9 - 9
  • [10] Interpretable and personalized CVD risk assessment: Innovative approaches
    Paredes, S.
    Henriques, J.
    Rocha, T.
    Valente, F.
    Carvalho, P.
    Morais, J.
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2021, 51 : 97 - 97
12345